In Silico Pharmacokinetics Studies for Quinazolines Proposed as EGFR Inhibitors

Gabriela Souza Fernandes¹, Michelle Bueno de Moura Pereira¹, Ana Cláudia Barbosa Marinho¹, Brisa Machado², Ana Carla Moreira², Matheus Puggina de Freitas³, Karen Luise Lang², João Eustáquio Antunes^2*

¹Department of Medicine, Federal University of Juiz de Fora, Governador Valadares, Brazil.
²Department of Pharmacy, Federal University of Juiz de Fora, Governador Valadares, Brazil.
³Department of Chemistry, Federal University of Lavras, Lavras, Brazil.

DOI: 10.4236/ojmc.2015.54007                

Abstract

In silico pharmacokinetics studies can aid the search for molecules with potential ability to be drug candidates. In this paper, a number of quinazoline candidates for epidermal growth factor receptor inhibitors—EGFR, important targets for the treatment of cancer, are computationally analyzed. The literature described that 69 quinazoline molecules were synthesized and the respective half maximum inhibitory concentrations (IC₅₀) were obtained. A bilinear parabolic model was built to investigate the druglikeness by correlating the corresponding lipophilicities, which can be represented by the ideal Log P , with the optimal biological activity in terms of pIC₅₀ values. Structural characteristics leading to improved pharmacokinetics parameters were then analyzed. Compound 56 exhibited the lowest IC₅₀ and, therefore, it had the highest ability to inhibit the EGFR. In the present work, the most potent inhibitor 56 is not calculated to be the most promising drug candidate, since it’s out of the parabolic model obtained due to a Log P above 5, which is not within the expected optimum range. Finally, this work is an example of computational prediction that an experimentally, highly active EGFR inhibitor can be unsuccessful as drug candidate because of pitfalls in pharmacokinetics parameters.

Keywords

Cancer Treatment, Quinazoline, Inhibitors, Rational Drug Design, Pharmacokinetics

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Thomas, G. (2012) Química Medicinal: uma introdução. Guanabara Koogan, São Paulo.
[2]	Barreiro, E.J. (2008) As Bases Moleculares da Ação dos Fármacos. 2th Edition, C.A.M, Porto Alegre.
[3]	Fraga, C.A.M. and Barreiro, E.J. (1996) Cardiotônicos: histórico e perspectivas de uma importante classe de agentes terapêuticos. Quimica Nova, 19, 182-189.
[4]	Kubinyi, H. (1977) Quantitative Structure-Activity Relations. 7. The Bilinear Model, a New Model for Nonlinear Dependence of Biological Activity on Hydrophobic Character. Journal of Medicinal Chemistry, 20, 625-629. http://dx.doi.org/10.1021/jm00215a002
[5]	Lombardo, F., Lipinski, C.A., Dominy, B.W. and Feeney, P.J. (1997) Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Setting. Advanced Drug Delivery Reviews, 23, 3-25. http://dx.doi.org/10.1016/S0169-409X(96)00423-1
[6]	http://www.molinspiration.com
[7]	http://www.molsoft.com/servers.html
[8]	Connolly, D.J., Cusack, D., O’Sullivan, T.P. and Guiry, P.J. (2005) Synthesis of Quinazolinones and Quinazolines. Tetrahedron, 61, 10153-10202. http://dx.doi.org/10.1016/j.tet.2005.07.010
[9]	Katritzky, A.R. and Pozharskii, A.F. (2003) Handbook of Heterocyclic Chemistry. Pergamon Press, Oxford.
[10]	Mhaske, S.B. and Argade, N.P. (2006) The Chemistry of Recently Isolated Naturally Occurring Quinazolinone Alkaloids. Tetrahedron, 62, 9787-9826. http://dx.doi.org/10.1016/j.tet.2006.07.098
[11]	Bridges, A.J., Zhou, H., Cody, D.R., Rewcastle, G.W., McMichael, A., Showalter, H.D., Fry, D.W., Kraker, A.J. and Denny, W.A.T. (1996) Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 39, 267-276. http://dx.doi.org/10.1021/jm9503613
[12]	Rahman, M.U., Rathore, A., Siddiqui, A.A., Parveen, G. and Yar, M.S. (2014) Synthesis and Characterization of Quinazoline Derivatives: Search for Hybrid Molecule as Diuretic and Antihypertensive Agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 29, 733-743. http://dx.doi.org/10.3109/14756366.2013.845820
[13]	Matsuda, H., Yoshikawa, M., Ko, S., Iinuma, M. and Kubo, M. (1998) Antinociceptive and Anti-Inflammatory Activities of Evodiamine and Rutaecarpine. Nature Medicine, 52, 203-208.
[14]	Buchanan, J.G. and Sable, H.Z. (1972) Selective Organic Transformations. Wiley-Interscience, New York.
[15]	Hibino, S. and Choshi, T. (2001) Simple Indole Alkaloids and Those with a Nonrearranged Monoterpenoid Unit. Natural Product Reports, 18, 66-87. http://dx.doi.org/10.1039/b004055j
[16]	Koepfly, J.B., Mead, J.F. and Brockman Jr., J.A. (1947) An Alkaloid with High Antimalarial Activity from Dichroa febrifuga. Journal of the American Chemical Society, 69, 1837-1837. http://dx.doi.org/10.1021/ja01199a513
[17]	Kacker, I.K. and Zaheer, S.H. (1951) Synthesis of Substituted 4-Quinazolones. Journal of Indian Chemical Society, 28, 344-346.
[18]	Amin, A.H., Mehta, D.R. and Samarth, S.S. (1970) Biological Activity in the Quinazolone Series. Progress in Drug Research, 14, 218-268. http://dx.doi.org/10.1007/978-3-0348-7075-7_5
[19]	Fry, D.W., Kraker, A.J., McMichael, A., Ambroso, L.A., Nelson, J.M., Leopold, W.R., Connors, R.W. and Bridges, A.J. (1994) A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase. Science, 265, 1093-1095. http://dx.doi.org/10.1126/science.8066447
[20]	Baselga, J. (2006) Targeting Tyrosine Kinases in Cancer: The Second Wave. Science, 312, 1175-1178. http://dx.doi.org/10.1126/science.1125951
[21]	Rewcastle, G.W., Denny, W.A., Bridges, A.J., Zhou, H., Cody, D.R., McMichael, A. and Fry, D.W. (1995) Tyrosine Kinase Inhibitors. Synthesis and Structure-Activity Relationships for 4-[(Phenylmethyl)amino] and 4-(Phenylamino) Quinazolines as Potent Adenosine 5’-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 38, 3482-3487. http://dx.doi.org/10.1021/jm00018a008
[22]	Levitzki, A. (2003) Protein Kinase Inhibitors as a Therapeutic Modality. Accounts of Chemical Research, 36, 462-469. http://dx.doi.org/10.1021/ar0201207
[23]	Vansteenkiste, J.F. (2004) Gefitinib (Iressa): A Novel Treatment for Non-Small Cell Lung Cancer. Expert Review of Anticancer Therapy, 4, 5-17. http://dx.doi.org/10.1586/14737140.4.1.5
[24]	Bonomi, P. (2003) Erlotinib: A New Therapeutic Approach for Non-Small Cell Lung Cancer. Expert Opinion on Investigational Drugs, 12, 1395-1401. http://dx.doi.org/10.1517/13543784.12.8.1395
[25]	Gilmer, T.M., Cable, L., Alligood, K., Rusnak, D., Spehar, G., Gallagher, K.T., Woldu, E., Carter, H.L., Truesdale, A.T., Shewchuk, L. and Wood, E.R. (2008) Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib Wood. Cancer Research, 68, 571-579. http://dx.doi.org/10.1158/0008-5472.CAN-07-2404
[26]	Traxler, P. (2003) Tyrosine Kinases as Targets in Ancer Therapy—Successes and Failures. Expert Opinion on Therapeutic Targets, 7, 215-234. http://dx.doi.org/10.1517/14728222.7.2.215
[27]	Vema, A., Panigrahi, S.K., Rambabu, G., Gopalakrishinan, B., Sarma, J.A.R.P. and Desiraju, G.R. (2003) Design of EGFR Kinase Inhibitors: A Ligand Based Approach and Its Confirmation with Structure Based Studies. Bioorganic & Medicinal Chemistry, 11, 4643-4653. http://dx.doi.org/10.1016/s0968-0896(03)00482-6
[28]	Golan, D.E. (2009) Principles of Pharmacology. 2nd Edition, Medicine & Health Science Books, New York.
[29]	Howland, R.D. and Mycek, M.J. (2008) Farmacologia Ilustrada. 3rd Edition, Artmed, São Paulo.
[30]	García-Echeverría, C., Traxler, P. and Evans, D.B. (2000) ATP Site-Directed Competitive and Irreversible Inhibitors of Protein Kinases. Medicinal Research Reviews, 20, 28-57. http://dx.doi.org/10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.0.CO;2-2
[31]	ACD/Labs Release 2012 (File Version 14.01, Build 65894), 17 Sep. 2013. www.acdlabs.com